OBJECTIVETo observe the clinical efficacy of warming Shen, enhancing Yang, invigorating qi, and nourishing blood method (WSEYIQNBM) combined artificial cycle therapy in treatment of premature ovarian failure (POF) patients of Shen yang deficiency syndrome (SYDS).

METHODSTotally 96 POF patients of SYDS were randomly assigned to the treatment group and the control group, 48 in each group. Patients in the treatment group were treated with WSEYIQNBM combined artificial cycle therapy, while those in the control group were treated with Western medicine artificial cycle therapy. One month constituted 1 course, a total of 3 courses. The menstruation and main symptoms were observed before and after treatment. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) were detected before and after treatment.

RESULTSThe total effective rate was 85.43% in the treatment group, higher than that of the control group (79.17%, P < 0.05). Besides, better effect in improving Chinese medical symptoms was obtained in the treatment group (P < 0.05).

CONCLUSIONPOF patients' serum hormone levels and clinical symptoms could be improved by WSEYIQNBM combined artificial cycle therapy.

Adult ; Drugs, Chinese Herbal ; therapeutic use ; Estradiol ; administration & dosage ; therapeutic use ; Female ; Humans ; Phytotherapy ; Primary Ovarian Insufficiency ; diagnosis ; drug therapy

Hepatoid carcinoma is a rare type of malignant tumor resembling hepatocellular carcinoma that arises in extrahepatic sites.(stomach, lung, ovary, pancreas, bladder and renal pelvis). Hepatoid carcinoma of the ovary is an extremely rare ovarian tumor, first described by Ishikura and Scully in 1987. Histologically it is important to differentiate this entity from other oxyphil tumors of the ovary as it requires aggressive treatment. We have experienced a case of hepatoid carcinoma of the ovary in 69-year-old postmenopausal woman, who has been treated with operation and adjuvant Taxol - cisplatin chemotherapy. We present this case with brief review of literatures.
Aged ; Carcinoma, Hepatocellular ; Cisplatin ; Drug Therapy ; Female ; Humans ; Lung ; Ovary ; Paclitaxel ; Pancreas ; Pregnancy* ; Primary Ovarian Insufficiency* ; Urinary Bladder

OBJECTIVE: To assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure. METHODS: Fourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured. RESULTS: The mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period. CONCLUSION: In the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial.
Chemotherapy, Adjuvant ; Drug Therapy* ; Female ; Fertility Preservation ; Follicle Stimulating Hormone ; Follow-Up Studies ; Gonadotropin-Releasing Hormone* ; Humans ; Ovarian Neoplasms ; Ovary ; Pregnancy ; Primary Ovarian Insufficiency ; Uterine Cervical Neoplasms

Adult ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Estrogens ; therapeutic use ; Female ; Humans ; Phytotherapy ; Primary Ovarian Insufficiency ; drug therapy ; Progesterone ; therapeutic use

OBJECTIVETo study the therapeutic efficacy of bushui roumu recipe (BRR) combined medroxyprogesterone acetate tablet (MAT) in treating premature ovarian failure (POF).

METHODSTotally 90 POF patients of Shen deficiency Gan stagnation syndrome were assigned to 3 groups by random number table, 30 in each group. Patients in the treatment group were treated with BRR and MAT, those in the Chinese medicine group were treated with BRR, and those in the Western medicine group were treated with artificial period method. All patients were treated for 3 months. The menstrual improvement was observed before and after treatment. The therapeutic efficacy was assessed using modified Kupperman scoring standard. The serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) were observed before and after treatment.

RESULTS(1) In aspect of the menstrual improvement: In the treatment group 20 patients had menstrual onset during the treatment course. Ten had normal menstruation after discontinued medication. Of them one got pregnancy one month after treatment. In the Chinese medicine group 6 patients had menstrual onset during the treatment course. Two had normal menstruation after discontinued medication. In the Western medicine group 26 patients had menstrual onset during the treatment course. Twelve had normal menstruation after discontinued medication. Better effects on the menstrual improvement were obtained in the treatment group than in the Chinese medicine group (P < 0.01), but with no statistical difference when compared with the Western medicine group (P > 0.05). (2) There was statistical difference in modified Kupperman scores of the 3 groups between before and after treatment (P < 0.01). The improvement of total modified Kupperman score was better in the treatment group than in the other two groups (P < 0.01). The improvement of palpitation was better in the treatment group than in the other two groups (P < 0.05). The improvement of tidal fever and sweat was better in the treatment group and the Chinese medicine group than in the Western medicine group (P < 0.05). (3) After treatment all patients' serum E2 was higher than before treatment, serum levels of FSH and LH were lower than before treatment. Compared pre- and post-treatment, there was statistical difference (P < 0.01). The serum E2 level in the 3 groups was higher after treatment than before treatment with statistical difference (P < 0.01). The levels of FSH and LH were lower in the 3 groups after treatment than before treatment with statistical difference (P < 0.01). The improvement of E2 was better in the treatment group than in the Chinese medicine group (P < 0.05). The improvement of FSH and LH was better in the treatment group than in the Western medicine group (P < 0.05).

CONCLUSIONCombination of BRR and MAT could improve the clinical symptoms, menstruation, and serum reproductive hormones in POF patients of Shen deficiency Gan stagnation syndrome.

Adult ; Amenorrhea ; drug therapy ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Medroxyprogesterone Acetate ; therapeutic use ; Phytotherapy ; Primary Ovarian Insufficiency ; drug therapy

Animals ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Estrogen Replacement Therapy ; Female ; Humans ; Ovulation Induction ; methods ; Phytotherapy ; Primary Ovarian Insufficiency ; drug therapy ; genetics

OBJECTIVETo observe the clinical effect on treatment of premature ovarian failure (POF) patients by Bushen Tiaojing Recipe (BTR) and hormone replacement therapy (HRT).

METHODSTotally 72 POF patients were randomly assigned to three groups by random digit table, i.e., the Chinese medicine group, the Western medicine group, and the integrative medicine group, 24 in each group. Those in the Chinese medicine group took BTR. Those in the Western medicine group were treated by HRT. Those in the integrative medicine group were treated by BTR + HRT. All were treated for three courses and followed-up for 3 months after treatment. The clinical efficacy, integrals of clinical symptoms, and serum sex hormones levels [follicular stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH)] were compared among the three groups before treatment, at the end of treatment, and 3 months after withdrawal.

RESULTS(1) The total effective rate was better in the integrative medicine group than in the Chinese medicine group and the Western medicine group (P < 0.05). (2) At the end of treatment, the integrals of clinical symptoms decreased in the 3 groups when compared with before treatment in the same group (P < 0.05, P < 0.01). The integrals of clinical symptoms were higher at 3 months after withdrawal than at the end of treatment in the Western medicine group (P < 0.05). But there was no statistical difference in changes of integrals between the Chinese medicine group and the integrative medicine group (P > 0.05). (3) By the end of treatment serum E2 increased (P < 0.01), FSH and LH decreased (P < 0.01) in the three groups, more significantly in the integrative medicine group and the Western medicine group (P < 0.05, P < 0.01). At 3 months after withdrawal serum E2 decreased, FSH and LH increased in the Western medicine group, showing statistical difference when compared with the other two groups (P < 0.05, P < 0.01). There was no statistical difference in changes of serum E2, FSH, or LH between the Chinese medicine group and the integrative medicine group (P > 0.05).

CONCLUSIONSBTR combined HRT had significant effect on treatment of POF, could significantly improve patients' clinical symptoms, menstrual states, and serum sex hormones levels. It had lower recurrence rate. Patients suffered from less adverse reactions.

Adolescent ; Adult ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Hormone Replacement Therapy ; Humans ; Integrative Medicine ; Phytotherapy ; Primary Ovarian Insufficiency ; drug therapy ; Young Adult

Premature ovarian failure (POF) is a kind of gynecological disease that causes amenorrhea, infertility, menopause and urogenital symptoms. Currently hormone replacement therapy (HRT) is the most popular choice for women with POF to get rid of menopausal syndrome. However, as the popularization of Chinese herbs made Chinese medicine (CM) shine new lights, physicians are able to treat POF with both meno-herbs and integrated therapy. HRT has its own indications and contraindications. For example, unexplained vaginal bleeding, acute liver damage, liver dysfunction, vascular embolization, and breast cancer are all contraindications of HRT, and CM is taken by more physicians as an adjuvant therapy. This review, including a range of common Chinese herbs and formulations according to the existing literature, provides a general description of CM treating POF from the aspects of mechanisms and clinical application. It also highlights acupuncture as a unique physiotherapy for POF. Although the validity of CM has been supported by the evidence of many preclinical trials, clinical trials and meta-analysis, the adverse events with CM therapy still exist and no guarantee has been made for its safety. This review concludes the updated information for CM treating POF contributing to further studies.
Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Infertility, Female ; etiology ; therapy ; Medicine, Chinese Traditional ; methods ; Menopause, Premature ; drug effects ; physiology ; Primary Ovarian Insufficiency ; complications ; therapy

OBJECTIVE: To evaluate the incidence of the +769 G/A mutation of inhibin-alpha gene in Korean patients with idiopathic premature ovarian failure. DESIGN: DNA analysis of the mutation. METHODS: One hundred patients with idiopathic premature ovarian failure (POF) were recruited. Patient with known causes of premature ovarian failure were excluded: cytogenetic abnormalities, prior chemotherapy, prior bilateral oophorectomy and autoimmune disease, etc. DNA was extracted from peripheral blood and the +769 G/A variant of Inhibin-alpha gene (INH-alpha) was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism using restriction enzyme BbvI. RESULTS: We didn't find any case of +769 G/A variant in Inhibin-alpha gene in 100 Korean patients with idiopathic POF. CONCLUSION: This result suggests that in contrary to the recent data reported on the Asian population, the +769 G/A variant in inhibin-alpha gene may not exist in Korean patients with idiopathic POF.
Asian Continental Ancestry Group ; Autoimmune Diseases ; Chromosome Aberrations ; DNA ; Drug Therapy ; Female ; Humans ; Incidence ; Ovariectomy ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Primary Ovarian Insufficiency*

Premature ovarian failure (POF) is defined as the complete cessation of menses less than 40 years of age. The criteria are more than four months of amenorrhea, with serum follicle stimulating hormone value of >40 mIU/mL and the frequency of POF is about 1% of all women. Although the etiologies of POF remain unknown, suggested factors are genetic, autoimmune, chemotherapy and environmental toxicants. The cytogenetic abnormalities predominantly concern the X chromosome, including Turner syndrome, Fragile X syndrome and deletion or translocation of X chromosome. We report a case of premature ovarian failure with the following karyotype: 46,X,der(X), t(X;11)(q28;p13).
Amenorrhea ; Chromosome Aberrations ; Drug Therapy ; Female ; Follicle Stimulating Hormone ; Fragile X Syndrome ; Humans ; Karyotype ; Primary Ovarian Insufficiency* ; Turner Syndrome ; X Chromosome*